COMP <GO>
NEUP vs RADX // EV/EBITDA & P/E VALUATION
Neuphoria Therapeutics Inc. (NASDAQ) VS. Radiopharm Theranostics Limited (NASDAQ) • 15-METRIC TALLY: NEUP 1
— RADX 1
■ METRIC PARITY
LAST: $3.05 (-0.33%) • MKT CAP: $16.6M
valuation
—
LAST: $1.08 (-3.26%) • MKT CAP: $16.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEUP VS. RADX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEUP | RADX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.80% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.47% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -7.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -2.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.4 | 43.7 | -17.30 | RADX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.6M | $16.1M | $417.2K | NEUP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEUP REV | RADX REV | NEUP GROSS % | RADX GROSS % | NEUP FCF | RADX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $15.6M | — | — | — | $77.2K | — |
| FY 2024 | $0 | — | — | — | -$14.7M | — |
| FY 2023 | $0 | — | — | — | -$14.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEUP // BETA —
RADX // BETA —